Tumour budding is an emerging prognostic biomarker in colorectal cancer (CRC) and other
solid cancers. Tumour buds are usually defined as isolated single cancer cells or clusters of …

Colorectal cancer (CRC), and breast, ovarian, pancreatic and prostate cancers are generally
considered as low immune-reactive cancers that represent either limited infiltration of …

The current pathological and molecular classification of pancreatic ductal adenocarcinoma
(PDAC) provides limited guidance for treatment options, especially for immunotherapy …

Purpose: Although abundant myeloid cell populations in the pancreatic ductal
adenocarcinoma (PDAC) microenvironment have been postulated to suppress antitumor …

Simple Summary Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive
and deadliest cancer worldwide, with an overall survival (OS) rate, all stages combined, of …

Simple Summary This review article presents a synopsis of the key clinical developments,
their limitations, and future perspectives in the treatment of pancreatic cancer. In the first part …

Simple Summary Electrochemotherapy and irreversible electroporation are primarily used
for treating patients with cutaneous and subcutaneous tumors and pancreatic cancer …

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid tumors. The tumor
immune microenvironment (TIME) formed by interactions among cancer cells, immune cells …

Abstract Background Tumour infiltrating lymphocytes (TILs) are a prognostic parameter in
triple-negative and human epidermal growth factor receptor 2 (HER2)-positive breast cancer …

Simple Summary Colorectal cancer (CRC) is one of the most common cancers worldwide.
Novel markers have been investigated in order to better predict the course of disease and …